Crinetics R&D Day updates preclinical pipeline: TSHR antagonist, SST3 agonist, NDC platform

Crinetics Pharmaceuticals, Inc.

CRN12755 (TSHR antagonist) decreased thyroid hormone (T4) in rat model and hyaluronic acid/IL-6 in TED patient orbital fibroblasts.
CRN10329 (SST3 agonist) reduced cystic index, kidney weight, and injury markers in ADPKD mouse model; SST3 highly expressed in cyst-lining cells.
CRN09682 (NDC) showed dose-dependent anti-tumor activity in mouse models; free MMAE persisted in tumor >240 hours, cleared from plasma by 24 hours.
Phase 1/2 BRAVESST2 trial of CRN09682 expects up to 150 participants; Phase 1 dose escalation: 3-6 patients per cohort.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.